Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Jacob

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
BMJ Open Diabetes Research & Care|January 19, 2022
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baselineRichard E Pratley, Stephan Jacob, Seungjae Baek, et al.
Metabolism: Clinical and Experimental|September 25, 2003
Interactions of conjugated linoleic acid and lipoic acid on insulin action in the obese Zucker ratMary K Teachey, Zachary C Taylor, Thomas Maier, et al.
Diabetes, Obesity & Metabolism|June 28, 2018
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetesDirk Müller-Wieland, Monika Kellerer, Katarzyna Cypryk, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivityClaus Thamer, Jürgen Machann, Oliver Bachmann, et al.
Diabetes, Obesity & Metabolism|July 9, 2019
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trialCees J Tack, Stephan Jacob, Cyrus Desouza, et al.
Journal of Hypertension|February 9, 2016
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trialJohn R Petrie, Steven P Marso, Stephen C Bain, et al.
Cardiovascular Diabetology|March 20, 2024
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomesOliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology|May 7, 2026
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuumOliver Schnell, Arnav Agarwal, Michel Azizi, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
BMJ Open Diabetes Research & Care|January 19, 2022
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baselineRichard E Pratley, Stephan Jacob, Seungjae Baek, et al.
Metabolism: Clinical and Experimental|September 25, 2003
Interactions of conjugated linoleic acid and lipoic acid on insulin action in the obese Zucker ratMary K Teachey, Zachary C Taylor, Thomas Maier, et al.
Diabetes, Obesity & Metabolism|June 28, 2018
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetesDirk Müller-Wieland, Monika Kellerer, Katarzyna Cypryk, et al.
The Journal of Clinical Endocrinology and Metabolism|April 8, 2003
Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivityClaus Thamer, Jürgen Machann, Oliver Bachmann, et al.
Diabetes, Obesity & Metabolism|July 9, 2019
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trialCees J Tack, Stephan Jacob, Cyrus Desouza, et al.
Journal of Hypertension|February 9, 2016
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trialJohn R Petrie, Steven P Marso, Stephen C Bain, et al.
Cardiovascular Diabetology|March 20, 2024
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomesOliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology|May 7, 2026
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuumOliver Schnell, Arnav Agarwal, Michel Azizi, et al.
Pageof 5